Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Table 2 Peficitinib treatment exposure and changes in peficitinib dose during the overall period (SAF)

	Total (N = 843)
Duration of peficitinib exposure, months¹
Mean (SD)	22.7 (17.4)
Max	70.7
Median	18.2
Min	0.1
Duration of initial peficitinib dose, months²
Mean (SD)	12.1 (11.7)
Max	70.7
Min	0.1
Treatment compliance rate (%)³
Mean (SD)	97.0 (3.5)
Dose increase, n (%)
No	489 (58.0)
Yes	354 (42.0)
1 dose increase	285 (33.8)
2 dose increases	63 (7.5)
≥ 3 dose increases	6 (0.7)
Dose decrease, n (%)
No	802 (95.1)
Yes	41 (4.9)
1 dose decrease	38 (4.5)
2 dose decreases	3 (0.4)
≥ 3 dose decreases	0
Maximum peficitinib dose, n (%)
50 mg	39 (4.6)
100 mg	561 (66.5)
150 mg	243 (28.8)

¹Duration of exposure for overall period (days) was calculated as: date of the last dose of study drug – date of initial dose of study drug + 1
²Duration from first peficitinib taken (50 mg for patients from RAJ1, 100 mg for patients from RAJ3 and RAJ4) up to first dose change was calculated
³Treatment compliance for overall period (%) was calculated as: 100 × (total number of tablets actually received in the overall period/total number of tablets planned to receive in the overall period)
SAF safety analysis set, SD standard deviation

ISSN: 1478-6362